
|Articles|June 1, 2004
Ruboxistaurin slows central DME, does not halt progression
Inhibition of PKC shown to affect changes in retinal blood flow as well as leukocyte adhesion
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
2
Glaucoma innovation: Eight themes to watch in 2026
3
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
4
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
5












































